The Silent Epidemic: Addressing the Unmet Need in Dry AMD

In the world of global health, numbers often tell the story before the symptoms do. Today, approximately 200 million people worldwide are living with Age-Related Macular Degeneration (AMD). By 2040, that number is projected to reach 288 million.

But the most critical statistic isn't the total prevalence; it is the disparity in care. 85–90% of these patients have the "dry" form of the disease. Yet, for decades, the vast majority of therapeutic innovation has focused on the "wet" form—leaving millions of dry AMD patients with a diagnosis but no destination.

At BioPhotonix, we are driven by the urgency of this silent epidemic. We are looking beyond the diagnosis to understand the structural gaps that have left so many patients behind.

The Cost of "Watch and Wait"

For patients diagnosed with early or intermediate dry AMD, the standard of care has historically been conservative: monitoring, lifestyle advice, and nutritional supplements. While valuable, these measures do not constitute active treatment.

This "watch and wait" approach carries a heavy human and economic toll. Research indicates that the annual economic burden of AMD in the US alone approaches $49 billion, with the majority of costs driven not by medical treatment, but by lost productivity and quality of life.

When patients lose their central vision, they don’t just lose the ability to read or drive; they lose their independence. The anxiety of uncertain progression—waiting for vision to decline—is a burden that patients and their families carry daily.

A Structural Misalignment

Why has this gap persisted? Our analysis suggests a fundamental misalignment in care delivery.

Dry AMD is typically diagnosed and monitored in community optometry—the primary care of the eye. However, traditional interventional technologies have been designed for hospitals and specialist centres. This disconnect creates a bottleneck: effective technologies exist, but they are often locked away in high-cost, low-access environments that cannot scale to meet the needs of millions of patients.

The market doesn't need another hospital-bound console. It needs a solution that fits where the patients are.

Bridging the Gap

BioPhotonix is not just developing a device; we are engineering a solution to this structural problem. Our progress over the last year has been dedicated to validating a delivery model that brings active intervention out of the specialist clinic and into the community.

We are building a future where:

• Intervention is accessible: Patients can access sight-preserving therapy in their local optometry practice, not just distant hospitals.

• Care is proactive: Clinicians are empowered to treat early, rather than waiting for irreversible decline.

• Independence is preserved: We shift the goal from "managing blindness" to "maintaining sight."

The technology to change the trajectory of dry AMD is within reach. The challenge now is accessibility. That is the challenge BioPhotonix is built to solve.